PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.79%
Revenue growth of 13.79% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
-55.89%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-110.68%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is -8.91%. Seth Klarman would check if external or internal factors caused the decline.
-110.68%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is -11.88%. Seth Klarman would check if structural or cyclical issues are at play.
-140.68%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is -5.99%. Seth Klarman would investigate factors dragging net income down.
-129.18%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is -1.07%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-128.65%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
40.06%
Share change of 40.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
37.54%
Diluted share change of 37.54% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-4001.79%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
29.11%
FCF growth of 29.11% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
428.38%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.27%. Joel Greenblatt might see a short-term competitive advantage at play.
-2160.23%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-519.63%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-44.26%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-325.17%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 5.78%. Seth Klarman might see a fundamental problem if peers maintain growth.
-1884.91%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 15.38%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-128.25%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 1.07%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4744.30%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 38.39% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
5474.80%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 50.14%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
1855.02%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 23.43%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-85.62%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
86.58%
Inventory growth of 86.58% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
52.33%
Asset growth of 52.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
11.30%
BV/share growth of 11.30% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-20.34%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
86.76%
R&D growth of 86.76% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
55.94%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.